The effect of maxacalcitol on cardiovascular disesase in hemodialysis patients

The effect of maxacalcitol on cardiovascular disesase in hemodialysis patients - MAX study

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002784

Enrollment

Registered

2009-12-01

Start date

2009-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic kidney disease

Interventions

Maxacalcitol therapy Conventional therpy (oral vitamin D treatment)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Hemodialysis patients Within 2 years after the initiation of hemodialysis therapy Serum intact PTH level more than 180pg/ml Serum corrected calcium level less than 10.0mg/dl

Exclusion criteria

Exclusion criteria: Post history of intravenous vitamin D therapy Post history of cicalcet HCl treatment Post history of peritoneal dialysis or kidney transplantion Pregnant woman Post history of severe cardiovascular disease

Design outcomes

Primary

Measure	Time frame
Left ventricular mass index	—

Secondary

Measure	Time frame
Intimal plus medial complex thickness Coronary artery calcification score Pulse wave velocity Dual energy X-ray absorptiometry Bone metabolism marker Inflamatory marker Oxidative stress marker Parathyroid gland volume Correlation between bone and artery Correlation between vitamin D level and vascular calcification	—

Countries

Japan

Contacts

Public ContactMasatomo Taniguchi

Kyushu University, Graduate School of Medical Sciences Department of Medicine and Clinical Science

masatomo@kcu.med.kyushu-u.ac.jp092-642-5256

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026